KPV vs Thymosin Beta-4
A side-by-side research comparison of KPV and Thymosin Beta-4 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | KPV | Thymosin Beta-4 |
|---|---|---|
| Full name | Lysine-Proline-Valine Tripeptide | Thymosin Beta-4 (Full Length) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation. | Sequesters G-actin to regulate cytoskeleton dynamics, promotes stem cell differentiation, and activates anti-inflammatory and anti-apoptotic pathways. |
| Molecular weight | 342.43 Da | 4921 Da |
| Half-life | ~2-3 hours | ~6-8 hours |
| Bioavailability | ~60-70% oral; higher subcutaneous | ~95% subcutaneous |
| Typical dose | 200-500 mcg per dose | 1-5 mg |
| Frequency | 1-2x daily | 2-3x per week |
| Route | Oral, topical, or subcutaneous | Subcutaneous injection |
KPV reported benefits
- Potent anti-inflammatory
- Gut inflammation reduction
- Skin condition improvement
- Immune modulation
Thymosin Beta-4 reported benefits
- Comprehensive tissue repair
- Cardiac regeneration
- Neurological recovery
- Corneal healing
- Anti-fibrotic effects
Related comparisons
Research and educational reference only. Not medical advice.